
Mayne Pharma reports quarterly EBITDA drop to $5.3M
Key points
- Mayne Pharma Group reported a 52% decrease in first-quarter underlying EBITDA to $5.3 million.
- First-quarter revenue fell 2% to $95.7 million, while the share price traded lower at $2.45.
- Strategic growth in the Women's Health segment was offset by expected competitive erosion in dermatology sales.
Mayne Pharma (ASX:MYX) reported a 52% drop in first-quarter underlying EBITDA to $5.3 million.
The quarterly underlying EBITDA fell from $11. Million in the prior corresponding period, while revenue slipped to $95.7 million.
"The first quarter of FY27 delivered continued strong prescription growth across our Women's Health portfolio, driven by our growth strategy, and saw further momentum in DistributeRx," said Mayne Pharma CEO Aaron Gray.
During the period, the business settled legacy generic drug pricing litigation for a one-time payment of US$0.7 million.
The business also entered into an exclusive five-year licensing deal with Italfarmaco for BLISSEL in Australia.
Following the announcement, the Mayne Pharma share price was down at $2.45.
Mayne Pharma operates as a speciality pharmaceutical business focused on commercialising branded and generic products.
The business continues to expand its digital pharmacy platform, DistributeRx, alongside its core portfolio offerings.
Frequently asked questions
More from Australia
ASIC chair flags retail demand for SpaceX, Anthropic offers
Mayne Pharma shares rise 81% on A$604m takeover
Chalmers flags A$52m tax compliance savings for businesses
Western Gold names Geraghty chairman amid A$7.5m placement
Black Rock secures US$5m CRDB early drawdown
Sharon AI net loss widens to US$43.8m
